FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have Symptomatic Plexiform Neurofibromas Not Amenable to Complete Resection By Ogkologos - March 20, 2025 870 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ReNeu study Source RELATED ARTICLESMORE FROM AUTHOR Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or GEJ Adenocarcinoma Advancing Childhood Cancer Research: A Conversation with Dr. Brigitte Widemann Azacitidine-Venetoclax Prolongs EFS Over Induction Chemotherapy Among Induction-Eligible Patients with AML MOST POPULAR How a Musician Copes With Life With Metastatic Breast Cancer March 17, 2021 Medical Assistant Diagnosed with Breast Cancer While Volunteering as Patient for... May 7, 2021 New study to detect oesophageal cancer earlier April 28, 2022 Research with integrity – the importance of communication November 14, 2022 Load more HOT NEWS Similar Efficacy Between Subcutaneous and Intravenous Pembrolizumab Given with Chemotherapy for... FDA Approves Belzutifan for Advanced Renal Cell Carcinoma Spotlight On: Pelvic Physical Therapists in Cancer Care New on NCI’s Websites for August 2024
